74 citations
,
April 2002 in “PubMed” This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.
31 citations
,
January 2008 in “Gynecological endocrinology” In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.
7 citations
,
August 2020 in “Health and Quality of Life Outcomes” This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.
October 2025 in “Minerva Obstetrics and Gynecology” This review suggests that estroprogestins with anti-androgenic progestins, like cyproterone acetate and drospirenone, may effectively manage androgen excess in PCOS women, considering individual patient profiles.
November 2023 in “Systems Biology in Reproductive Medicine” This study assessed vitamin E and a combined oral contraceptive's impact on continuous light-induced PCOS in female rats, finding they reduced testosterone levels and modified oxidative stress, suggesting benefits via melatonin-related pathways.